Join Medicilon at SITC 2024 in Houston

Ready to Meet Medicilon at SITC's 39^th Annual Meeting & Pre-Conference Programs (SITC2024)?

We are happy to meet you in person to discuss how our services and capabilities can support your research and expedite your drug discovery and development activities.

Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers. Medicilon has built a one-stop service platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide (Non-clinical Research for Cellular Immunotherapies）

Date: November 6-10, 2024

Location: George R. Brown Convention Center in Houston, TX

Medicilon Booth#707

About SITC2024

SITC 2024 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.

About Medicilon

Medicilon is a leading global integrated pharmaceutical R&D service contract research organization (CRO), providing a full range of one-stop preclinical R&D services, in compliance with Chinese and international regulatory filing standards, to pharmaceutical companies and research institutions world-wide. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry.

20 Years of Excellence

500+ IND Approved by FDA, NMPA, EMA, and TGA

2000+ Active Clients Worldwide

2600+ Scientists & Research Staff

85,000+ m² Lab Space

At Medicilon, we are dedicated to support our clients develop their research and discovery programs from initial concept through the IND filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.